ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial

Study limitation reported by the research below: “All participants were Japanese adults; results may not generalize to other ethnic populations given known differences in metabolic risk profiles and BMI thresholds.”

Papers